Market
Signs contract to supply drug substance for oligonucleotide therapeutics Contract represents 27.5% of annual revenue
ST Pharm has signed a 91.3 billion won contract to supply drug substance for oligonucleotide therapeutics to a global biotech company based in the United States.
ST Pharm disclosed on the 18th that it had signed a single sales and supply contract for drug substance for oligonucleotide therapeutics. The confirmed contract value is 91,332,435,000 won, equivalent to 27.54% of its 2025 consolidated revenue of 331,681,282,447 won.
The counterparty is a global biotech company based in the United States whose primary business is new drug development. ST Pharm said it has fulfilled contracts of the same type with the company over the past 3 years.
The sales and supply regions include the United States and Europe, and the contract runs from today through November 22, 2027. The products will be manufactured in-house.
The contract value is $66,135,000. The conversion to won used the final announced basic exchange rate of 1,381.0 won per dollar from KEB Hana Bank on the previous day, the 17th.
ST Pharm added that, at the counterparty's request for confidentiality, it would defer disclosure until November 22, 2027. The contract value and term may change at the counterparty's request or for other reasons.
BIOBOOK TEAM
biobookmedia@biobook.co.kr
United Therapeutics, Liquidia Reach $380 Million Settlement, Ending Tyvaso Patent Dispute
Galderma to Expand Dermatology Portfolio With $1.5 Billion Acquisition of Zo Skin Health
Stryker invests $400 million in CMR Surgical, secures exclusive U.S. sales rights for surgical robot
Vera signs deal with Gilead worth up to $1.9 billion, sees 'opportunity for additional deals'
Zealand partners with ‘AI protein’ developer Generate in $1.6 billion deal to expand obesity drug pipeline
Remed to Issue 10 Billion Won in Convertible Bonds to Fund Expansion in North America, Japan and Europe
